Seven Abstracts Accepted for Presentation at ASCO
SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Exelixis,
Inc. (Nasdaq: EXEL) will hold an investor and analyst briefing in
conjunction with the 44th Annual Meeting of the American Society of
Clinical Oncology (ASCO) from 6:00 p.m. to 8:00 p.m. CT on Monday, June 2,
-- George A. Scangos, PhD, President and Chief Executive Officer
-- Michael M. Morrissey, PhD, President of Research and Development
-- Gisela M. Schwab, MD, Executive Vice President and Chief Medical
-- XL184 (targets: MET, VEGFR2, RET)
-- XL147 (targets: PI3K)
-- XL765 (targets: PI3K, mTOR)
-- XL647 (targets: EGFR, HER2, VEGFR2)
-- XL880* (targets: MET, VEGFR2)
-- XL281 (targets: RAF)
* XL880 was selected by GlaxoSmithKline in December 2007 for further
development and commercialization.
The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.
An archived replay of this webcast will be available until 9:00 p.m.
PT/12:00 a.m. ET on July 2, 2008. Access numbers for this replay are:
1-888-286-8010 (domestic) and +1-617-801-6888 (international); the replay
passcode is: 42662164.
Saturday, May 31
-- XL647 (EGFR, HER2, VEGFR2) -- Poster & Discussion
"A phase 1 study of XL647, an EGFR, HER2, VEGFR2 inhibitor,
administered orally daily to patients (pts) with advanced solid
Day: Saturday, May 31
Session: Developmental Therapeutics: Molecula
|SOURCE Exelixis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved